ClinicalTrials.gov
ClinicalTrials.gov Menu

Proper Dosage of Ketamine in Intravenous Regional Anesthesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00221871
Recruitment Status : Unknown
Verified September 2005 by University Health Network, Toronto.
Recruitment status was:  Recruiting
First Posted : September 22, 2005
Last Update Posted : October 11, 2006
Sponsor:
Information provided by:
University Health Network, Toronto

Brief Summary:
Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Condition or disease Intervention/treatment Phase
Pain. Drug: Different dosages of Ketamine Not Applicable

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).
Study Start Date : January 2004
Study Completion Date : January 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anesthesia
Drug Information available for: Ketamine





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18-70
  2. Weight: 50-100 kg
  3. ASA: I, II, III
  4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

  1. Contraindication to IVRA such as sickle cell disease.
  2. Any known hypersensitivity reaction to Ketamine.
  3. History of chronic pain or regular medication with analgesics.
  4. History of opioid dependence.
  5. Drug of alcohol abuse.
  6. Psychiatric disorder.
  7. Allergy to acetaminophen or codeine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221871


Contacts
Contact: Colin McCartney, MD (416)603-5118 colin.mccartney@uhn.on.ca

Locations
Canada, Ontario
University Health Network Recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Filomena Valle-Leutri, BSc    (416)603-5800 ext 2016    filomena.valle-leutri@uhn.on.ca   
Principal Investigator: Colin McCartney, MD         
Sub-Investigator: Vincent Chan, MD         
Sub-Investigator: Philip Peng, MD         
Sub-Investigator: Paul Tumber, MD         
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Colin McCartney, MD University Health Network, Toronto

ClinicalTrials.gov Identifier: NCT00221871     History of Changes
Other Study ID Numbers: UHN02-0233-A
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: October 11, 2006
Last Verified: September 2005

Additional relevant MeSH terms:
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action